Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQBF7O)

Drug Name
MK-3222 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hairy cell leukaemia 2A82.2 Phase 3 [1]
Plaque psoriasis EA90.0 Phase 3 [2]
Psoriasis vulgaris EA90 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMQBF7O

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Not Available [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hairy cell leukaemia
ICD Disease Classification 2A82.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-23 (IL23) DTT IL23A 5.37E-01 -0.1 -0.42
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8093).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.